Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Teleflex Inc.

Start price
Target price
Perf. (%)
€320.00
-
2.50%

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
buy
Dexcom Inc.

Start price
Target price
Perf. (%)
€328.95
€350.00
0.20%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Sustainability is important
Higher risks for its business
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€34.83
€37.00
1.55%

Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
3.58%

EBIT growth >5% per year expected
Very low/no dividend yield expected
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
3.58%

EBIT growth >5% per year expected
Very low/no dividend yield expected
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
3.58%

EBIT growth >5% per year expected
Very low/no dividend yield expected
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€36.24
€40.00
-2.40%

Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€36.17
€26.00
-2.21%

buy
Becton, Dickinson & Co.

Start price
Target price
Perf. (%)
€222.00
€260.00
-9.98%

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€38.44
€50.00
-7.99%

Could be worthwhile Investment >10% per year
buy
Star Equity Holdings Inc.

Start price
Target price
Perf. (%)
€3.16
€30.00
-7.28%

Could be very worthwhile Investment >20% year
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€1.43
€10.00
-32.87%

Could be very worthwhile Investment >20% year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€69.30
-
-7.79%

buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€69.30
-
-7.79%

buy
Medtronic plc

Start price
Target price
Perf. (%)
€97.71
-
-0.79%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Known brand
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€39.22
€75.00
-9.82%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€60.00
€77.00
0.00%

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€60.00
€77.00
0.00%

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€60.00
€77.00
0.00%

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€36.97
€50.00
-4.33%

Top 10 in its market
Small cyclical dependencies
Below average Management
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€34.41
€40.00
2.79%

Could be very worthwhile Investment >20% year
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Thermo Fisher Scientific Inc.

Start price
Target price
Perf. (%)
€406.60
€400.00
-8.15%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€12.90
-
-33.33%

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Risky balance sheet
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€9.45
-
-8.99%

Probably not worthwhile Investment
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€9.90
-
-13.13%

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group